Member Info for nlondon1234

Acmsy.I think accustem will do better than tils.Well i'm banking on it.Tils just have awful investor comms.

The problem is like anything tils, all we seem to get nowadays is those stupid bloomberg smallcap repeats.Clearly the us don't like us.Neither the instituions are interested nor retail investors.Just imagine how long a full Nasdaq listing will take... Accustem spinoff took much longer than people were expecting.

By the time we waited for accustem spinoff, it was a disaster and the sp was hugely down.Great.

This will take ages as usual and tils shareholders won't be able to hold us shares in their accounts.What about some real news GC for the 10 million option you took from the huge amount raised to progress the company next year?Plus as all lths not the US hate us and constantly short us.Anyway!!Rant over.

Told you all!

It rns's less than Tils, like never.I don't even know what it does.I don't think they ever do investor presentations to tell folk either or those darn bloomberg smallcap interviews that have so impressed us investors recently.

A third of that 30 mill disappeared on a bonus for GC last year for the sp reaching a certain target.However unfortunately it should have been firmly linked with clinical progress targets.I was willing to forgive but give us something solid GC.

Problem is you can never totally exclude placing risk with smallcaps.N4p have a good chance now as ever i think but then admittedly everyone has an opinion.If n4p did raise a huge amount, that would be great news as they are not likely to raise a huge amount unless there is some amazing news.I don't think they are about to start a self funded trial or anything but that would be something that required a big capital outlay obviously.

Institutional shareholders and analysts covering these smallcaps are rare (although there are a few aim focussed funds about, although it wouldn't surprise me if most of them are in the big aim success story names, Asos, etc..) , but can equally be an opportunity.

We need an RNS detailing some update.Anything but one of those bloomin smallcap Bloomberg interviews please.

Nevermind the British market, the US institutional market, nevermind retail will go crazy if Bezos and Gates start getting going on our licence.Just a waiting game as who knows.. could be tomorrow.. could be months.

However great a share's potential.Never buy with your partner's money as especially if it takes off and does amazing.. eventually something will go wrong with one share or another and it will cause problems in your relationship.It ain't worth the gains.

AI companies are seriously entering/ doing well in several different sectors nowadays.The billionaires are using it allover the shop to make processes and businesses more efficient and it is working.

Should be some news on one front or another sooner rather than later.

Wise strategy alibro as if it keeps you from sleeping and you start dreading looking at rns's or get overly excited on good news and prospects, aim can be a very cruel master/mistress at times indeed.Not the jog board afaik, but others are full of vultures.

If you don't invest in us growth stocks i would recommend looking there as the ftse hasn't got many and hasn't grown in years, whilst the s&p500 has.US growth stocks tend to be much better managed, have big pre-ipo venture funds and institutional funds invested and able to raise finance at higher marketcaps much more easily.Thus you can get the potential reward without worrying about the risk and being diluted to dust by the time your investment comes in.

Easy money here.Helium's hot right now.

No view on copl here.Aim has always been heavily skewed against the private punter.Last year was an overexuberance outlier with virtually everything going up, more private punters than ever in the markets and at home and some with spare funds or furlough and seeing alot of markets going up.Now alot of folk have gone back to work and the markets aren't so fun.So it is a bit harder work and every other share won't bag every other week anymore in my opinion.

Well after an initial big 'growth' year if the patent case is successful and the ip is still wanted and hasn't been out engineered by somebody (like big tech is sometimes wont to do with all their r&d expenses), i would expect a decent p/e multiple.

I'm not sure many companies (although i know nanoco could have a sudden competitive advantage, there is still nanosys to be valued around £750 million i believe as the main competition) could maintain a 50% growth rate of sales or earnings for long.

Nanoco desperately need earnings and a much higher marketcap anyway so they can get bank debt, raise more at much less dilution and re-invest in r&d.That's half the value and game in the tech sector or they risk getting left behind.No ip maintains its value forever.

Are they selling big %s of wte for a loss then?Makes no sense.More like than the typical aim investor than institutions.

Plus most folk have returned to work now (more at the office too) with any spare furlough money they might have had!

The market was irrationally overexuberant last year.It's just back to aim as usual.Much more likely to negatively bag by 50% over time (nevermind overnight) than double your money in a week, like last year.Some years you will have trends on aim with more or less interest in o&g or gold minnows for example.. and others something else perhaps or just quieter allround for a bit.